The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.Viking Therapeutics (VKTX 11.31%) stormed the stock market on Wednesday. Shares of the up-and-coming biotech rose by more than 11% not on any proprietary news from the company, but on an analyst's initiation of coverage. That performance was more than enough to top the trajectory of the bellwether S&P 500 index, which rose by slightly over 1% on the day.32% upside potential, analyst bel ...